New treatment option for adolescents with PKU now available.
- FDA approval expands treatment options for adolescents
- Palynziq offers a new approach to managing PKU
- Biomarin continues to innovate for rare diseases
The U.S. Food and Drug Administration (FDA) has granted approval for Biomarin's Palynziq (pegvaliase-pqpz) to treat adolescents aged 12 years and older diagnosed with phenylketonuria (PKU). This approval introduces a new treatment option aimed at managing the metabolic disorder, which impacts the body's ability to process phenylalanine, an amino acid found in many protein sources. Palynziq is designed to help lower blood phenylalanine levels for those struggling to maintain appropriate levels.
This approval follows clinical trials that demonstrated the drug’s effectiveness in reducing blood phenylalanine concentrations, providing an alternative for patients who have not adequately responded to existing dietary interventions. Palynziq is a biologic treatment administered via subcutaneous injection and is expected to be a significant advancement in addressing the unique challenges faced by adolescents living with PKU. With this new therapy, adolescents now have broader treatment possibilities to manage their condition.
Palynziq, developed by Biomarin, is already established as a treatment for adult patients with PKU. The expansion of indication to include adolescents 12 years and older signifies a critical step in the ongoing pursuit to enhance patient quality of life and outcomes. Continued research and observation will be essential in understanding the long-term effects and benefits of Palynziq in younger populations.
